Haleon (LSE:HLN) Stock May Be 47% Below Fair Value On Cash Flow

Haleon has delivered a 10.0% share price gain over the past three years, yet its recent softer run raises a simple question for investors who care about cash flows. Are the pounds you pay for Haleon today adequately backed by the cash the business is expected to produce over time, or has the share price moved ahead of that story?

• The 10.0% return over three years puts real money on the line for holders who now need to know whether those gains rest on solid cash flow foundations.
• This consumer health group leans heavily on established brands and recurring demand, which can support relatively steady cash generation and shapes how sensitive its intrinsic value is to small changes in long term assumptions.
• Prefer to judge Haleon on earnings? See what Haleon's 18.5x P/E says about the price.

The issue now is whether Haleon’s current share price is fully supported by the cash flows implied in its Discounted Cash Flow (DCF) intrinsic value estimate.

If you want to stress test this same cash flow question beyond Haleon, you can scan a wider set of companies through 15 high quality undervalued stocks.

Does Haleon Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the pounds of cash Haleon can return to shareholders over time. Over the last twelve months, the group produced roughly £2.5b of free cash flow, which is a solid base for any valuation built around cash generation rather than accounting profit.

Analysts feeding this DCF have input assumptions that show Haleon’s free cash flow increasing in absolute terms over the coming decade, then slowing into more modest expansion as a mature consumer health business. Those projections, once discounted back, put the estimated intrinsic value substantially above the current share price of £3.41. That gap suggests the market price is not fully reflecting the cash flows implied by the Discounted Cash Flow (DCF) model. Find out what Haleon could be worth using our Discounted Cash Flow (DCF) estimate.

The Haleon Narrative: What Would Justify Today's Price?

Narratives pick up where that valuation gap leaves off for Haleon and spell out which paths on revenue, profit margins and earnings would push the stock meaningfully above or below today’s price. They sit on Simply Wall St’s Community page. Rather than relying on a single model output, each one lays out the key assumptions behind its view of fair value so you can track them against future reported numbers.

Bulls see Haleon as a cash generative consumer health group with more to give, while bears worry that growth credibility and margins cap the upside.

Bull case: 9% undervalued

This view comes from the analyst consensus Narrative on Simply Wall St. It leans on forecasts across oral health, emerging markets and efficiency gains.

"Expansion in therapeutic oral health, where Haleon holds a leading position and has seen its oral health business grow at roughly 7% CAGR over more than a decade…"

Discover why this Narrative puts Haleon at 9% undervalued.

Bear case: 18% overvalued

This angle is taken from the bearish analyst Narrative on Simply Wall St. It leans more on execution risk and softer growth delivery.

"Although Haleon continues to talk up premium, clinically supported oral health launches that have historically outgrown the wider category, the group is still only delivering 2.6% organic revenue growth in the first half of 2026 against a 4% to 6% ambition…"

Explore why this Narrative puts Haleon at 18% overvalued.

Before acting on Haleon’s valuation, weigh who is steering the ship

Numbers only tell part of the story for Haleon, since the decisions, incentives and pay structures shaping leadership behavior can either reinforce or undercut any valuation case. See who runs Haleon and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com